Boise Kidney & Hypertension Institute’s Research Division aims to set the standard in clinical research. With an overriding concern for patient safety, BKHI Research Division provides premier research professionals to conduct all clinical trial related activities with the utmost accuracy and timeliness, while ensuring personable and professional patient care and conduct.
Boise Kidney has been conducting research in the Treasure Valley since opening in 2005. Our team has written and conducted investigator initiated trials to further the areas of chronic kidney disease, anemia management, and dialysis treatment standards of care. Boise Kidney has also participated in many pharmaceutical sponsored clinical research trials for a variety of indications including: Anemia, Catheter Occlusion, Home Hemodialysis, Artery Calcification, Diabetes, and Hypertension.
Under the direction of Arnold Silva, MD, PhD, Boise Kidney & Hypertension Institute partners with Frenova Renal Research to conduct clinical trials. Frenova Renal Research, a Fresenius Medical Care North America company, is the only Phase I-IV drug and device clinical development services provider dedicated exclusively to renal research. Frenova provides access to the largest renal research site network in the world.
Boise Kidney & Hypertension Institute is a member of the Frenova F1RST Up alliance, a highly select group of sites chosen for their expertise in renal research and track record of rapid patient recruitment and retention.
- Boise Kidney Research Director:
- Arnold Silva, MD, PhD
- Currently Enrolling Studies:
For more information about each trial, click on the links below.
Click: Trial Information | Identifier: NCT02876835
Sponsor: GlaxoSmithKline – Anemia
Multi-center event driven study in Non-dialysis participants with Anemia associated with Chronic Kidney Disease.
Click: Trial Information | Identifier: NCT02865850
Sponsor: Akebia – Anemia
Treatment of Anemia in subjects with Dialysis-dependent Chronic Kidney Disease.
Click: Trial Information | Identifier: NCT02942407
Sponsor: Christopher Granger/Bristol Meyer Squibb – Atrial Fibrillation
This is a prospective, randomized, open-label, blinded end-point evaluation trial. The patient population consists of patients on Hemodialysis who have Atrial Fibrillation (AF) and End-stage Renal Disease (ESRD).
Click: Trial Information | Identifier: NCT03019185
Sponsor: Reata – CARDINAL – Alport Syndrome
This international, multi-center, Phase 2/3 trial will study the safety, tolerability, and efficacy of bardoxolone methyl in qualified patients with Alport Syndrome. The Phase 2 portion of the trial will be open-label and enroll up to 30 patients. The Phase 3 portion of the trial will be double-blind, randomized, placebo-controlled and will enroll up to 180 patients.
Click: Trial Information | Identifier: NCT03366337
Sponsor: Reata – PHOENIX – T1D, IgAN, FSGS, ADPKD
This multi-center, open label Phase 2 trial will study the safety, tolerability, and efficacy of bardoxolone methyl in qualified patients with the following rare chronic diseases (CKD): CKD associated with type 1 diabetes, IgA nephropathy (IgAN), focal segmental glomerulosclerosis (FSGS), and autosomal dominant polycystic kidney disease (ADPKD). Patients will be enrolled in disease specific cohorts within the trial, and effectiveness of bardoxolone methyl in treating CKD will be assessed separately by cohort for each rare disease.
Click: Trial Information | Identifier: NCT02836574
Sponsor: inRegen – T2DM, Diabetic Nephropathy
The purpose of the present study is to compare the safety and efficacy of up to 2 injections of NKA given 3 to 6 months apart (maximum) in subjects who are randomized to receive their first treatment as soon as the NKA product is made available versus subjects who are randomized to undergo contemporaneous, standard-of-care treatment for CKD during the first 12 18 months prior to receiving up to 2 injections of NKA.
Click: Trial Information | Identifier: NCT03427125
Sponsor: Ardelyx – Hyperphosphatemia
This Phase 3, 26-week, open label study with a 12-week, placebo-controlled, randomized withdrawal period followed by an open label long term safety extension will evaluate the safety and efficacy of Tenapanor to treat hyperphosphatemia in end-stage renal disease (ESRD) on hemodialysis and peritoneal dialysis.
Click: Trial Information | Identifier: NCT03281538
Sponsor: Cara Therapeutics, Inc. – Uremic Pruritus
Open-label multicenter, long-term extension safety study to evaluate the safety of IV CR845 administered after each dialysis session over a Treatment Period of up to 52 weeks.